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Abstract  31 
 32 
Background Functional neurological disorder (FND), previously known as conversion disorder, is 33 
common and often results in substantial distress and disability. Previous research lacks large sample 34 
sizes and clinical surveys are most commonly derived from neurological settings, limiting our 35 
understanding of the disorder and its associations in other contexts. We sought to address this by 36 
analysing a large anonymised electronic psychiatric health record dataset.  37 
 38 
Methods Data were obtained from 322 patients in the South London and Maudsley NHS Foundation 39 
Trust (SLaM) who had an ICD-10 diagnosis of motor FND (mFND) (limb weakness or disorders of 40 
movement or gait) between 1st January 2006 and 31st December 2016. Data were collected on a range 41 
of socio-demographic and clinical factors and compared to 644 psychiatric control patients from the 42 
same register.  43 
 44 
Results Weakness was the most commonly occurring functional symptom. mFND patients were more 45 
likely to be female, British, married, employed pre-morbidly, to have a carer, and a physical health 46 
condition, but less likely to have had an inpatient psychiatric admission or to receive benefits. No 47 
differences in self-reported sexual or physical abuse rates were observed between groups, although 48 
mFND patients were more likely to experience life events linked to inter-personal difficulties.  49 
 50 
Conclusions mFND patients have distinct demographic characteristics compared to psychiatric 51 
controls. Experiences of abuse appear to be equally prevalent across psychiatric patient groups. This 52 
study establishes the socio-demographic and life experience profile of this under-studied patient 53 
group and may be used to guide future therapeutic interventions designed specifically for mFND.  54 
 55 
 56 
 57 
 58 
 59 
 60 
 61 
 62 
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Background     63 
Functional Neurological Disorder (FND), also known as conversion disorder, refers to a spectrum of 64 
neurological symptoms which have no known conventional neurological cause and are assumed 65 
psychological in origin (American Psychiatric Association, 2013). A wide range of symptoms and signs 66 
are reported, the commonest are seizures, sensory symptoms (e.g. numbness or visual impairment) 67 
or motor symptoms (e.g. limb weakness, tremor, dystonia or gait disorders). FND may begin suddenly, 68 
progress quickly, increase with attention or excessive fatigue, and disappear with distraction (Espay, 69 
2018).  70 
Establishing a population prevalence of FND is difficult due to changes in its terminology, diagnostic 71 
criteria, and the need for neurological examination prior to diagnosis. Evidence suggests its incidence 72 
is 4 to 5 per 100,000 of the population per year (Binzer et al., 1997, Akagi et al., 2001). A large study 73 
of neurology outpatients in Scotland found functional symptoms were the second most common 74 
disorder after headache, affecting 16% of patients (Stone et al., 2010a), a finding recently replicated 75 
in an Australian neurology practice (Ahmad et al., 2016). 76 
Previous studies have shown higher rates of females with FND, usually in the range of 60-80% (Villain, 77 
2017, McCormack et al., 2014, Carson et al., 2016), lower socio-economic status (Binzer et al., 1997), 78 
lower educational attainment (Deka et al., 2007, Stone et al., 2004) as well as lower mood and higher 79 
anxiety (Stone et al., 2010b, Binzer et al., 1997), although the evidence on this is mixed (van der 80 
Hoeven et al., 2015). Views regarding the connection between ethnicity and FND have been expressed 81 
over the years, usually along the lines that somatic manifestations of distress occur more in those from 82 
non-Western backgrounds (Lambo, 1956, Kleinman, 1982, Kleinman, 1980), although comparing rates 83 
is difficult due to the disparity in sampling methods and measures used as well as the diagnostic 84 
criteria employed (Brown et al., 2011) 85 
Childhood sexual and physical abuse rates are higher in FND compared to neurological disorders or 86 
healthy controls (Roelofs et al., 2005b, Ludwig et al., 2018, Sharpe et al., 2006). Studies in neurology 87 
settings report lower abuse rates compared to studies in psychiatry settings (Ludwig et al., 2018). 88 
Estimating the rates of abuse is challenging and depends on the type of measures used and the skill 89 
of the interviewer, among other factors. 90 
Patients with functional symptoms had the same rate of paid employment as patients with symptoms 91 
that were ‘largely’ or ‘completely’ explained by organic conditions, however amongst unemployed 92 
patients, patients with functional symptoms were more often unemployed due to ill health and were 93 
more  likely to receive incapacity benefit and disability living allowance (Carson et al., 2011). The 94 
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higher rate of benefits is likely explained by the increased physical and mental ill health experienced 95 
by functional cases in this study. Functional disorders occur in all areas of medicine and often result in 96 
chronic and severe symptoms with attendant high health and social care costs. Bermingham et al. 97 
(2010) reported that the incremental cost incurred by somatising patients is £3 billion per year, 98 
accounting for 10% of total NHS expenditure. 99 
Most studies on motor FND (mFND) have originated in neurology clinics, and are characterised by low 100 
sample sizes and lack control groups (Factor et al., 1995, Garcin, 2018, van der Hoeven et al., 2015, 101 
Schrag et al., 2004, Ertan et al., 2009, Binzer et al., 1997, Crimlisk et al., 1998). This could lead to 102 
overestimates of abuse risk and co-morbid psychiatric disorders and underestimates of physical illness 103 
comorbidities.  104 
This study addresses the imbalance in knowledge on mFND patients within psychiatric settings. We 105 
aimed to establish the socio-demographic, health and clinical characteristics, and possible symptom 106 
precipitants of mFND patients referred to a large psychiatric NHS Trust and compare outcomes to an 107 
otherwise random sample of psychiatric patients derived from the same database but matched for 108 
time of presentation. 109 
Methods 110 
Design and source of clinical data 111 
This was a case-control study of mFND patients in contact with secondary mental health services in 112 
South London and Maudsley (SLaM) Foundation Trust between 1st January 2006 and 31st December 113 
2016. Data were obtained from the SLaM Biomedical Research Centre’s (BRC) ‘Clinical Records 114 
Interactive Search’ (CRIS) database. The database contains anonymised electronic health records from 115 
SLaM, the largest provider of secondary mental health care in Europe. CRIS holds records on over 116 
250,000 anonymised individuals referred to SLaM services (Perera et al., 2016). This is a single online 117 
system where daily activities, medication, diagnoses, correspondence, health scores and all patient 118 
information is recorded. Relevant records can be retrieved using search terms of the database’s 119 
structured fields such as diagnoses or from searches of free text fields (for example clinical notes and 120 
correspondence).  121 
Study setting and participants 122 
SLaM provides inpatient and community services for a catchment population of over 1.5 million 123 
people living in southeast London and also receives national referrals for FND. All participants were 124 
receiving mental healthcare in SLaM. 125 
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mFND cases included all patients aged over-18 with a primary or secondary diagnosis of ‘Conversion 126 
disorder with motor symptom or deficit’ (ICD-10 code: F44.4). Patients with any F44 diagnosis and 127 
evidence of functional motor symptoms in unstructured case notes or correspondence were also 128 
included as were patients with a confirmed mFND diagnosis in their case notes. See “Supplementary 129 
Materials” for a comprehensive list of the search strategies.   130 
Our control group comprised contemporaneous SLaM patients who received any non-functional (i.e. 131 
non-F44) psychiatric diagnosis on the succeeding day the mFND patient received their diagnosis. 132 
Patients aged under-18 and those with a neurodegenerative disease of old age or an intellectual 133 
disability (F70 – F79) diagnosis were excluded. We used a random number generator from the website, 134 
random.org to select controls from the search list and adopted a case-control ratio of 1:2.  135 
Ethical approval 136 
CRIS has received ethical approval from the Oxfordshire Research Ethics Committee C 137 
(08/H0606/71+5) as an anonymised dataset for mental health research. Ethical approval as an 138 
anonymised database for secondary analysis was granted in 2008, and renewed for a further five years 139 
in 2013.  This study was approved by a patient-led NIHR BRC CRIS oversight committee (CRIS 14-101). 140 
Outcome measures 141 
Data were extracted from structured fields in CRIS (e.g. dates and diagnoses) and unstructured clinical 142 
notes and correspondence. Socio-demographic characteristics included date of birth, gender, 143 
ethnicity, marital status, receipt of welfare benefits, housing status, employment and pre-morbid 144 
employment status and type. Clinical data included age at psychiatric symptom onset, the nature of 145 
cases’ motor symptoms, smoking status, psychiatric inpatient history, and comorbid physical health 146 
conditions.  147 
Information about experiences of physical or sexual childhood or adult abuse exposure was collected 148 
from free text notes. Where no mention of abuse was mentioned, this was coded as ‘not known’ and 149 
removed from frequency calculations. The rate of unknown information is reported.  150 
Any available information on possible symptom precipitants was collected from CRIS’s unstructured 151 
text. All references in patients’ clinical records to possible precipitants were noted, which comprised 152 
any noted life event, at any stage of their life. This information was taken from referral letters, 153 
clinicians’ notes and case reviews. No exclusion criteria were applied and categorisation of events 154 
occurred after data collection. Events were then classified as those occurring in early life and events 155 
occurring after the age of 18. Our method is similar to the qualitative classification method utilised 156 
with the same database by Bell et al. (2018). 157 
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Statistical analysis 158 
SPSS for Windows (SPSS v21.0, Chicago, Illinois, USA) and Microsoft Excel (Microsoft Office 159 
Professional Plus 2010, Version 14.0.7015.1000) were used to analyse data. Socio-demographic and 160 
clinical characteristics were analysed using descriptive statistics. Proportions were used to describe 161 
categorical data, and means and standard deviations for continuous variables. Odds ratios (OR) with 162 
95% confidence intervals compared unadjusted event rates. Two binary logistic regression analyses 163 
were performed to compare socio-demographic characteristics of mFND patients with control 164 
patients and precipitating events respectively.  165 
Results 166 
Socio-demographic characteristics  167 
Our search returned 322 mFND and 644 control patients.  168 
The control group comprised patients with mood disorders (22.7%), mental and behavioural disorders 169 
due to psychoactive substances (17.4%), schizophrenia, schizotypal and delusional disorders (14%), 170 
factors influencing health status and contact in health services (Z00 – Z99) (13.8%), unspecified mental 171 
disorders (F99) (11.3%), neurotic, stress and somatoform disorders (10.9%), behavioural syndromes 172 
associated with physiological disturbances (2.6%), behavioural and emotional disorders with onset in 173 
childhood and adolescence (2.2%), disorders of personality and behaviour (1.9%) and other disorders 174 
(3.2%).  175 
The socio-demographic and clinical characteristics of the mFND patients are described in Table 1. 176 
There were 238 females (73.9%) and 84 males (26%) in the mFND group, a significantly higher 177 
proportion of females compared to control patients (OR: 2.52, 95% CI: 1.9 – 3.4, p = 0.001).  178 
The mean age of mFND patients’ was 46.1 years (SD = 13.4) versus 47.6 years (SD = 16.2) for controls 179 
(not significantly different). The mean age at which mFND patients first began experiencing psychiatric 180 
symptoms was 33.2 years (SD: 14.6), similar to that of control patients (32.5 years, SD: 17.8). 181 
British patients constituted 60.6% of the mFND group, compared to 50.9% in the control group (OR: 182 
1.5, 95% CI: 1.1-1.9, p = 0.001). mFND patients were more likely to be married, in a civil partnership 183 
or cohabiting (43.4%) compared to 17.7% in the control group (OR: 4, 95% CI: 2.9 – 5.4, p = 0.001).  184 
mFND patients were more likely to employed than control patients (24.5% versus 17.4%, OR: 1.5, 95% 185 
CI: 1.1 – 2.2, p = 0.02). Employment was stratified by gender, but no differences between groups 186 
emerged. Control patients were more likely to receive welfare benefits (55.7%) compared to mFND 187 
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patients (47.8%) (OR: 0.73, 95% CI: 0.55 – 0.96, p = 0.03). Of patients receiving benefits, mFND patients 188 
were more likely to receive Disability Living Allowance compared to controls (χ2 = 17.7, df = 1, p = 189 
0.001). 190 
In total, 19% of mFND and 8% of control patients were employed or had been employed in care-giving 191 
roles in health, social care, child care, or mental health sectors (OR: 2.63, 95% CI: 1.73 – 4, p = 0.001).  192 
Patients were grouped according to whether they were carers to a family member or friend, either 193 
formally or informally. mFND patients were significantly more likely to act as carers (9.8%) than control 194 
patients (2.8%) (OR: 3.77, 95% CI: 2 – 7.1, p = 0.001). The significant difference was maintained in both 195 
males and females after stratification by gender.  196 
38.8% of mFND patients themselves had a carer compared to 23.5% of control group participants (OR: 197 
2.06, 95% CI: 1.5 – 2.8, p = 0.001). The significant difference was maintained when data were stratified 198 
by gender.  199 
Health 200 
 201 
The type of motor and sensory symptoms affecting mFND patients was categorised. Most participants 202 
had more than one symptom, with the mean number of functional motor and sensory symptoms 203 
equalling 2.42 (SD: 1.1). The most commonly reported symptom was ‘weakness’ of any type 204 
accounting for 50.3% of all reported symptoms, followed by ‘other’ motor or sensory symptoms 205 
(37.9%) such as visual disturbances, facial droop etc., and ‘tremor’ which includes ‘tremor, spasms, 206 
jerks and tics’ (33.9%). Figure 1 outlines the rate of motor, sensory and other co-morbid functional 207 
symptoms.  208 
 209 
A third (33.8%) of all mFND patients had a comorbid functional diagnosis. The most common 210 
syndromes were non-epileptic seizures (16.2% of all mFND patients), irritable bowel syndrome (7.5%) 211 
and somatoform pain disorder (4.3%). Four per cent of patients had co-morbid functional diagnoses 212 
classified as ‘other’. These include depersonalisation disorder, psychogenic polydipsia, dissociative 213 
amnesia, foreign accent syndrome, somatoform disorder and dissociative identity disorder. Figure 1 214 
outlines co-morbid functional diagnoses. There were significantly more co-morbid functional 215 
diagnoses in the mFND group than the 1.9% in the control group (OR: 26, 95% CI: 14 – 48.2, p = 0.001).  216 
38.5% of mFND patients smoked cigarettes at the time of data collection, significantly fewer than 217 
controls at 62.6%, see Table 1. A significantly higher proportion of mFND patients had a co-morbid 218 
physical health condition compared to control patients (74.5% versus 59.6%, OR: 1.9, 95% CI: 1.4 – 219 
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2.7, p =0.001), with ‘diseases of the nervous system’ the most common illness in mFND patients, 220 
accounting for 22.2% of all reported illness.   221 
More control than mFND patients had at least one psychiatric inpatient admission (43.5% versus 222 
33.2%). Control patients spent more days in inpatient settings with a mean of 143.3 days (SD: 209, 223 
median: 67, IQR: 155) compared to mFND patients’ mean of 130.3 days (SD: 124) (median: 112 days, 224 
IQR: 89, U = 11944.5, p = 0.007)We assessed whether there were reports of mental health problems 225 
in patients’ family members. There was a positive history in 52.1% of mFND patients and 60% of 226 
control patients, with no statistical difference. Amongst mFND patients, the most common relative 227 
reported to have a mental health problem were patients’ mothers (accounting for 30.4% of all 228 
relatives), followed by fathers (18.2%) and patients’ sons (6.1%). Similar patterns were observed in 229 
the control group and there were no statistical differences between groups. 230 
Abuse 231 
We examined clinical records for experience of childhood sexual abuse (CSA), childhood physical 232 
abuse (CPA) and physical or sexual abuse in adulthood. No information was available on the presence 233 
or absence of CSA in 22.4% of mFND patients and 39.9% of control group patients. The rate of CSA in 234 
the mFND group was 20%, similar to the 21.9% rate in the control group (OR: 0.9, 95% CI: 0.6 – 1.3, p 235 
> 0.05). When stratified by gender, the CSA rate in female mFND patients was 22.8% and 30.3% in 236 
female control patients. CSA rates in male mFND patients were 11.3% and 11.2% in male control 237 
patients. Using odds ratios, comparing female abuse rates in both groups to females not experiencing 238 
abuse, there was no statistical difference, with the same finding amongst males.  239 
Information on the presence or absence of CPA was lacking in 22% of mFND patients and 40.2% of 240 
control patients. There was no difference in the rate of CPA in the mFND group (22.7%) compared to 241 
the control group at 21.8%. When stratified by gender, 24.3% of female mFND patients experienced 242 
CPA compared to 27.1% of female control patients. The rate in male mFND patients was 17.7% and 243 
15.8% in control patients. 244 
No information was available on adult physical or sexual abuse in 20.2% of mFND patients and 37.9% 245 
of control group patients. The rate of adult physical or sexual abuse in mFND patients was 27.2% which 246 
did not significantly differ from the rate in the control group of 21%. All comparisons are outlined in 247 
Table 1).   248 
Predictors of mFND  249 
To assess the socio-demographic variables that might predict an mFND diagnosis, we conducted a 250 
binary logistic regression analysis performed amongst all patients with a diagnosis of mFND. mFND 251 
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was the dependent variable and our independent variables are outlined in Table 1. The overall 252 
prediction was 57.1% in this model. The Cox and Snell pseudo R-square was 0.45, indicating that the 253 
fit of the model to the data was moderate.  254 
In the adjusted model, factors that predict an mFND diagnosis include being female (OR: 2.5, 95% CI: 255 
1.2 – 5.1, p = 0.01), married (OR: 7.6, 95% CI: 3.4 -17, p = 0.001), pre-morbidly employed (OR: 4.9, 95% 256 
CI: 1.7 – 14, p =0.003), receiving benefits (OR: 2.4, 95% CI: 1.1 – 5.2, p = 0.03), having a carer (OR: 2.8, 257 
95% CI: 1.4 – 5.7, p = 0.005), having a physical health condition (OR: 3.9, 95% CI: 1.9 – 8.1, p = 0.001) 258 
and being less likely to have a psychiatric admission (OR: 0.4, 95% CI: 0.2 – 0.7, p = 0.03). Britishness, 259 
being employed, a social or health care worker, carer to family member, smoking status and history 260 
of CSA, CPA and experience of sexual or physical abuse in adulthood were not significant predictors of 261 
mFND status in the adjusted model.  262 
Life experiences  263 
 264 
While sexual and physical abuse rates did not differ between groups, we conducted an examination 265 
of other potential precipitants. 266 
The classification of events in childhood and adulthood are outlined in Table 2. In the unadjusted 267 
analysis, a significantly lower proportion of mFND patients reported taking drugs under the age of 18 268 
(1% v. 6.6%, p = 0.002), and a higher proportion of mFND patients experienced bullying before the age 269 
of 18 compared to the control group (17.8% v. 9.1% p = 0.001). Following stratification by gender, this 270 
significant difference remained for both men and women.  271 
For events in adulthood, the unadjusted analysis found mFND patients experienced significantly 272 
higher rates of workplace, school or university problems compared to the control group (22.6% v 6.9%, 273 
p = 0.001), were more likely to be involved in a legal dispute (7% v 0.8%, p = 0.001), to report problems 274 
within a sexual relationship (32.1% v 23.2%, p = 0.006), to have experienced an accident or assault 275 
(15.3% v 2.3%, p = 0.001), to be affected by war or political upheaval (6.9% v 3.3%, p = 0.02), to have 276 
an unwell family member (22% v 6.4%, p = 0.001), and to have had an organic  illness or injury 277 
precipitating their symptom onset (23.3% v 7.3%, p = 0.001). mFND patients were significantly less 278 
likely to report abusing drugs or alcohol compared to the control group (8% v. 29%, p = 0.001).  279 
A binary logistic regression analysis accounting for gender, age and all other life events produced 280 
similar odds ratios however the adjusted model found no difference in proportions of those taking 281 
drugs aged under-18, or those involved in legal disputes.  282 
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Discussion 283 
Main findings 284 
Research on mFND patients is limited. To our knowledge, the current study is the largest of its kind in 285 
this patient group. We identified 322 mFND patients from a mental health service case register of 286 
250,000 patient records. The associations between mFND and life events, demographic, social, 287 
occupational, and health characteristics were investigated and compared to a large unselected 288 
contemporaneous sample of patients with other mental health disorders.  289 
It is well-established that mFND has a female preponderance (Stone et al., 2009, Stone et al., 2010a, 290 
McCormack et al., 2014, Binzer et al., 1997), again confirmed in our study. Women may be more likely 291 
to perceive and label noxious bodily sensations as a result of heightened body vigilance (Warner, 292 
1995), societal gender differences may persuade more women to communicate bodily distress 293 
(Mechanic, 1972) or seek help for somatic symptoms from medical experts (Nathanson, 1977). There 294 
may be underlying genetic vulnerabilities, personality predispositions (McCrae et al., 2000), and 295 
hormonal differences could mediate responses to stressful life events leaving women more vulnerable 296 
to symptom development (Li et al., 2017). Alternatively, clinicians may be more likely to diagnose FND 297 
in women or specifically ask about experiences of trauma or abuse due to cultural and historical 298 
stereotypes of ‘hysteria’ as a specifically female malady.  299 
Evidence on level of education and socio-economic status (SES) in mFND is mixed. Some studies report 300 
no difference in SES or education between cases and neurological or healthy controls (van der Hoeven 301 
et al., 2015, Roelofs et al., 2005a, Stone et al., 2010b), with others reporting lower education in mFND 302 
patients (Binzer et al., 1997, Stefansson et al., 1976). We do not have a measure of SES but proxy 303 
measures show increased SES in mFND patients compared to controls. Contrary to some stereotypes, 304 
mFND patients were less likely to receive benefits, were more likely to be employed pre-morbidly and 305 
were more likely to be married, even when gender was controlled. The argument that less educated 306 
patients might use functional symptoms as a coping mechanism is not borne out in this study. These 307 
findings (and others) emerged because of what we contend to be a fair comparison with other 308 
psychiatric service users where employment is expected to be lower, and receipt of benefits, higher 309 
than the national average. 310 
Employment in care-giving positions within health and social care industries amongst mFND patients 311 
is worth noting. Studies in movement disorders clinics have found no difference between mFND 312 
patients and controls (Perry et al., 2017, Kenney et al., 2007), although McCormack et al. (2014) report 313 
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high rates of this employment. One theory is that working in healthcare roles or observing unwell 314 
family members allows the modelling of neurological symptoms (Shill et al., 2006, Hotopf et al., 2018). 315 
Our adjusted regression analysis did not find any difference in paid care work between mFND and 316 
control patients. Gender is likely to partly account for the relationship between employment in the 317 
health and social care industry and mFND status. Employment data supports this as healthcare 318 
workers account for 6% of the UK’s economy; and four-fifths are women (Yar et al., 2006). Similar 319 
trends in gender are seen in the status of non-paid carers. Census data from the Office for National 320 
Statistics (2011) found 58% of all carers are female. A combination of age and gender likely predicts 321 
carer status as in the general population, the peak age of caring is between 50 – 64 years of age, but  322 
one in four women aged 50-64 have caring responsibilities compared to one in six men of the same 323 
age.   324 
In our study, weakness, or the loss of motor function, was the most common functional motor 325 
symptom. Studies from movement clinics report tremor as the most prevalent functional symptom 326 
(Hinson et al., 2006, van der Hoeven et al., 2015, Kranick et al., 2011, Park, 2018), reflecting a possible 327 
referral bias to those clinics. Weakness has been described as the most common functional symptom 328 
in an acute stroke centre (Gargalas et al., 2015), a tertiary psychiatric inpatient setting (McCormack et 329 
al., 2014) and a neurological clinic (Crimlisk et al., 1998). While weakness was common, in our study 330 
most patients had more than one functional symptom, a finding reported elsewhere (Stone et al., 331 
2010b). Our cross-sectional design restricted us from establishing the evolution or prognosis of 332 
symptoms but it is likely symptoms do not remain static and can worsen or improve with time. 333 
We found mFND patients were less likely to have a hospital admission compared to controls. While we 334 
do not know why patients were admitted or if admissions were voluntary or involuntary, it is likely that 335 
the majority of mFND admissions were to the Lishman Unit, a specialist rehabilitation centre. Amongst 336 
control patients, those with an admission history were most commonly schizophrenia, schizotypal and 337 
delusion disorder and affective disorder patients, meaning they likely had qualitatively different kinds 338 
of admissions.In our unadjusted analysis, mFND patients were less likely to smoke than controls. We 339 
hypothesised that this might be due to the high proportion of schizophrenia patients in our control 340 
group. In a sensitivity analysis, we removed patients with a schizophrenia diagnosis from the control 341 
group but the significant difference in smoking remained. In our adjusted model however, the 342 
difference disappeared, a finding similar to a general practice survey comparing patients with 343 
persistent medically unexplained symptoms to those with medical diagnoses (Dirkzwager et al., 2007). 344 
Nonetheless, while smoking rates are certainly no higher than other psychiatric groups, the rate of 345 
smoking of 38.5% in mFND patients is substantially higher than the population prevalence in English 346 
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adults of 19% (Health and Social Care Information Centre, 2015). This may be surprising in a group 347 
which one could argue may be more health-anxious or body-focused. Smoking might help reduce 348 
patients’ anxiety or emerge due to distorted health behaviour beliefs. Future studies examining 349 
patients’ knowledge of general health advice might help explain this and other health behaviours.  350 
Life events 351 
We found no significant differences in rates of childhood sexual or physical abuse or adulthood sexual 352 
or physical abuse between groups.  353 
The 20% rate of CSA is slightly lower than previously reported in functional disorders in psychiatric 354 
settings, which range from 24% - 26.3% (Roelofs et al., 2002, Akyuz et al., 2017, Sar et al., 2004) (this 355 
excludes studies which select only non-epileptic seizure patients). Similarly, our CPA rate of 22.7% is 356 
moderately lower than previously reported rates in psychiatric settings, which varies between 23-28% 357 
(Nicholson et al., 2016, Farooq et al., 2016, McCormack et al., 2014, Roelofs et al., 2002). Our rates 358 
are also lower than those reported in a recent meta-analysis which reported CSA and CPA rates of 24% 359 
and 30% respectively, although this includes heterogeneous functional symptoms and service settings 360 
(Ludwig et al., 2018).  361 
The somewhat lower childhood abuse rates reported in our study may be an underestimation due to 362 
the observational, retrospective method and lack of structured interviewing, as studies utilising 363 
interview techniques report higher CSA rates in FND (Ludwig et al., 2018). In our study, no mention of 364 
abuse in clinical records was classified as missing data but this may mask 5-10% of the true event rate. 365 
There were higher levels of missing data on abuse in control group patients compared to mFND 366 
patients, suggesting clinicians may be more likely to ask about trauma and childhood history in mFND 367 
patients.   368 
This potential lack of methodological sensitivity would be expected to affect both groups equally. 369 
When stratified by gender, rates of childhood sexual and physical abuse are higher amongst females 370 
in both groups compared to their male counterparts, suggesting risk of childhood abuse is higher 371 
amongst females, but not a specific risk amongst female mFND patients. That abuse rates did not 372 
differ between mFND and control patients is an important finding which contradicts some theories of 373 
FND aetiology. There is evidence that in case-control studies, rate differences are attenuated when 374 
psychiatric controls rather than neurological or healthy controls are used (Ludwig et al., 2018). 375 
Perhaps more pertinent is that abuse is prevalent in the general public with retrospective surveys 376 
estimating CSA rates in English women of 11 – 17% (Bebbington et al., 2011, Gorey et al., 1997, Molnar 377 
et al., 2001, Office for National Statistics, 2016). Abuse experiences are likely to increase risk for 378 
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psychiatric morbidity generally and form a component of some patients’ mFND development, but our 379 
findings suggest they should not be regarded as specific to the disorder or be used as a diagnostic 380 
indicator. 381 
Perhaps more promising in the identification of specific risks in mFND aetiology are the findings on life 382 
events prior to symptom onset. Premorbid life experiences appear to be linked to disrupted or 383 
problematic inter-personal relationships; a finding echoed elsewhere where mFND patients had 384 
higher rates of family conflict (Akyuz et al., 2017, Stone et al., 2004). In some cases, functional 385 
symptoms may be a means, to help shape, negotiate or re-define problematic social interactions (see 386 
Nicholson et al., 2016). Evidence exists for reduced or impaired emotional processing in FND (Waller 387 
et al., 2006, Demartini et al., 2014) and this might disrupt the development of early inter-personal 388 
skills. The causal pathway is unlikely to be linear as the existence of functional symptoms may 389 
themselves exacerbate or undermine personal interactions and relationships. Where such a processes 390 
play a role in symptom development, patients might benefit if the management of inter-personal 391 
conflicts and the bolstering of inter-personal skills were incorporated into psychotherapeutic 392 
approaches for the condition.  393 
Strengths and limitations 394 
The strength of this study is its large sample size. The study uses an innovative source to access a larger 395 
sample of patients than would be possible to recruit in clinical research. Full electronic health records 396 
retrieved through the CRIS database enabled access to detailed information about mFND patients and 397 
their contact with psychiatric services. The use of a psychiatric control group allowed for the empirical 398 
test of differences in patient profiles and characteristics. Our sample is more representative of the 399 
population of patients seen in routine clinical care than would be the case in a typical clinical trial.  400 
Part of our search strategy involved a search of free-text clinical notes. Given the ubiquity of synonyms 401 
associated with a functional diagnosis, it is possible our search terms were not exhaustive and more 402 
mFND patients were present in the database than were detected in our study. Secondly, while our 403 
sample can be taken as encompassing a representative greater London NHS psychiatric catchment-404 
area population, it also included referrals to a tertiary neuropsychiatry service placing limitations on 405 
our ability to generalise findings to services without specialist neuropsychiatry input and to other NHS 406 
Trusts outside London. It is likely our mFND patients include more severely affected patients and of 407 
course our study only represents mFND patients who have had at least some contact with psychiatric 408 
clinical services. Thirdly, clinicians’ own biases or preferences in clinical formulations and note writing 409 
will have shaped the free-text clinical records, although this bias is unlikely to be systematic or to 410 
affect our between-group comparisons. Furthermore, we have emphasised factual information, albeit 411 
14 
 
uncorroborated over clinical interpretation. Finally, it was not possible to blind the researcher to case-412 
control status so we cannot discount the possibility of observer bias in data extraction.  413 
In conclusion, mFND patients have distinct demographic characteristics when compared to psychiatry 414 
controls attending the same NHS Trust. While some of our findings are unsurprising, such as the 415 
female preponderance and chronicity, reliance on carers, and associations with life stress, others are 416 
not necessarily in line with the clinical stereotypes of the mFND patient. For example there was no 417 
increase of CSA; ethnic background and nationality were less diverse, there were fewer hospital 418 
admissions and there were higher levels of employment. By establishing the socio-demographic and 419 
life experience profile of this under-studied patient group we hope to stimulate novel psychosocial 420 
interventions. 421 
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Table 1 Binary logistic regression analysis of socio-demographic factors associated with a motor FND (F44.4) diagnosis compared to a psychiatry control group  
  
mFND 
n (%) 
Control 
group 
n (%) 
Unadjusted 
OR 
  
Adjusted 
OR1 
 
p value 
  95% CI p value 95% CI 
Gender Female 238 (73.9) 341 (53) 2.52 1.9 – 3.4 0.001 2.5 1.2 – 5.1 0.01 
 Male 84 (26.1) 303 (47) Reference   Reference   
Ethnicity British 195 (60.6) 328 (50.9) 1.5 1.1 – 1.9 0.005 1.7 0.9 – 3.2 > 0.05 
 Any other ethnic group 127 (39.4) 316 (49.1) Reference   Reference   
Marital 
status 
Married, civil partner or cohabiting 141 (43.4) 111 (17.7) 4 2.9 – 5.4 0.001 7.6 3.4 - 17 0.001 
Single, divorced, separated, widowed 163 (53.6) 515 (82.3) Reference   Reference   
Work Employed 73 (24.5) 104 (17.4) 1.5 1.1 – 2.2 0.01 1 0.4 – 2.5 > 0.05 
 Unemployed 225 (75.5) 492 (82.6) Reference   Reference   
 Employed pre-morbidly 246 (87.5) 385 (75) 2.34 1.6 – 3.5 0.001 4.9 1.7 – 14 0.003 
 Not employed pre-morbidly 35 (12.5) 128 (25) Reference   Reference   
 Receives benefits 143 (47.8) 337 (55.7) 0.73 0.6 – 0.9 0.03 2.4 1.1 – 5.2 0.03 
 Does not receive benefits 156 (52.2) 268 (44.3) Reference   Reference   
Carers Social or health care worker  54 (19) 46 (8.2) 2.63 1.7 – 4 0.001 1.6 0.6 – 4.0 > 0.05 
 Non-social or health care worker 230 (81) 515 (91.8) Reference   Reference   
 Carer to family or friends 28 (9.8) 16 (2.8) 3.77 2 – 7.1 0.001 1.1 0.3 – 5.0 > 0.05 
 Not a care to family or friends 257 (90.2) 553 (97.2) Reference   Reference   
 Patients has a carer 107 (38.8) 128 (23.5) 2.06 1.5 – 2.8 0.001 2.8 1.4 – 5.7 0.005 
 Patients without a carer 169 (61.2) 416 (76.5) Reference   Reference   
Health Smoker 70 (38.5) 206 (62.2) 0.38 0.3 - 0.6 0.001 0.8 0.4 – 1.5 > 0.05 
 Non-smoker 112 (61.5) 125 (37.8) Reference   Reference   
 Physical health condition 219 (74.5) 326 (59.6) 1.9 1.4 – 2.7 0.001 3.9 1.9 - 8.1 0.001 
 No physical health condition 75 (25.5) 221 (40.4) Reference   Reference   
 Psychiatric inpatient stay 107 (33.2) 280 (43.5) 0.65 0.5 – 0.9 0.002 0.40 0.2 – 0.7 0.03 
 No psychiatric inpatient stay 215 (66.8) 364 (56.5) Reference   Reference   
Abuse History of child sexual abuse 50 (20) 85 (21.9) 0.89 0.6 – 1.3 > 0.05 1.1 0.5 – 2.6 > 0.05 
 No history of child sexual abuse 200 (80) 302 (78.1) Reference   Reference   
 History of child physical abuse 57  (22.7) 85 (22.1) 1.03 0.71 – 1.5 > 0.05 0.8 0.3 – 2.0 > 0.05 
 No history of child physical abuse 194 (77.3) 300 (77.9) Reference   Reference   
 History of adult SA or PA 70 (27.2) 84 (21) 1.4 0.98 – 2 > 0.05 1.9 0.8 – 4.6 > 0.05 
 No history of adult SA or PA 187 (72.8) 316 (79) Reference   Reference   
SA: sexual abuse, PA: physical abuse 
1 Adjusted for gender, age, ethnicity, marital status, employment status, pre-morbid employment status, benefit receipt, social or health care worker status, 
caring for family or friends, having a carer, smoking status, the presence of a physical health condition, stay in a psychiatry inpatient setting, history of child 
sexual abuse, history of child physical abuse, history of adult sexual or physical abuse 
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Table 2 Binary logistic regression of possible precipitant events occurring in childhood or adulthood associated with motor FND (F44.4) diagnosis compared to a psychiatry control group 
  
mFND 
n (%) 
Control  
group  
n (%) 
Un-
adjusted 
OR 95% CI 
p  
value 
Adjusted 
OR2 95% CI 
p 
 value 
Events in 
childhood 
Left or abandoned by a parent as a child1 30 (10.5) 37 (7.1) 1.5 0.9 – 2.5 > 0.05 1.1 0.5 – 2.4 > 0.05 
Violence between parents1 15 (5.3) 31 (6) 0.87 0.46 – 1.6 > 0.05 0.5 0.2 - 1.2 > 0.05 
Parents divorced or separated1 38 (13.2) 63 (12.2) 1.1 0.7 – 1.7 > 0.05 1.2 0.6 - 2.2 > 0.05 
In care, fostered or adopted as a child1 14 (4.9) 35 (6.8) 0.7 0.4 – 1.3 > 0.05 0.9 0.4 – 2.5 > 0.05 
Bullied in primary or secondary school1 51 (17.8) 47 (9.1) 2.16 1.4 – 3.3 0.001 2.0 1.1 – 3.7 0.03 
Took drugs under-181 3 (1) 34 (6.6) 0.15 0.05 – 0.5 0.002 0.3 0.6 – 1.5 > 0.05 
Events in 
adulthood 
Financial difficulties (e.g. debt, homelessness)1 35 (12.2) 59 (11.4) 1.08 0.7 – 1.7 > 0.05 1.5 0.7 – 3.1 > 0.05 
Bereavement but unlikely a precipitant1 49 (17.1) 64 (12.4) 1.5 0.97 -2.2 > 0.05 1.5 0.9 – 2.7 > 0.05 
Bereavement as likely precipitant1 54 (18.8) 75 (14.5) 1.4 0.9 – 2 > 0.05 1.6 0.9 – 2.9 > 0.05 
Interpersonal problems in the workplace, 
school or university1 
65 (22.6) 36 (6.9) 3.9 2.5 – 6.1 0.001 4.6 2.4 – 8.9 0.001 
Involved in a legal dispute1 20 (7) 4 (0.8) 9.6 3.3 – 28 0.001 7.0 0.7 – 70 > 0.05 
Problems within a sexual relationship (e.g. 
divorce)1 
92 (32.1) 120 (23.2) 1.6 1.1 – 2.2 0.006 1.7 1 – 2.9 0.04 
Accident or assault but unlikely a precipitant1 19 (6.6) 9 (1.7) 4 1.8 – 8.9 0.001 10.3 2.6 – 40.6 0.001 
Accident or assault a likely precipitant1 44 (15.3) 12 (2.3) 7.6 3.9 – 14.7 0.001 5.8 2.2 – 15.3 0.001 
Affected by war or political turmoil1 20 (6.9) 17 (3.3) 2.2 1.13 – 4.3 0.02 5.5 1.9 – 15.9 0.002 
Socially isolated1 5 (1.7) 9 (1.7) 1 0.3 – 3 > 0.05 1.1 0.1 – 8.0 > 0.05 
Abusing drugs or alcohol1 23 (8) 150 (29) 0.2 0.13 – 0.3 0.001 0.3 0.6 – 1.4 0.001 
Family member unwell1 63 (22) 33 (6.4) 4.1 2.6 – 6.5 0.001 5.2 2.7 – 9.9 0.001 
Organic illness or injury1  67 (23.3) 38 (7.3) 3.8 2.5 – 5.9 0.001 5.7 3 – 10.9 0.001 
Complication in pregnancy (e.g. postnatal 
depression, miscarriage or still birth)1 
22 (10.4) 33 (11.7) 0.88 0.5 – 1.6 > 0.05 0.5 0.2 – 1.1 > 0.05 
1 Reference: Patients not experiencing the event    
2 Adjusted for gender, age, & life events    
 
 
